Fast Pace of Activity in Next-Generation Sequencing Continues

News provided by

Jan 23, 2017, 08:08 ET

ROCKVILLE, Md., Jan. 23, 2017 /PRNewswire/ -- Change is the only constant in the market for next-generation sequencing, according to Kalorama Information, as the technology continues to hold promise in clinical settings. The market opportunity is evidenced by a number of acquisitions, financing rounds, product launches, and approvals, but six events stand out. Kalorama continues to track the sequencing market, which had an estimated $3.8 billion in product revenues in 2015. Additional information and segmentation of the sequencing market can be found in the firm's latest report, Next-Generation Sequencing Markets (report: http://www.kaloramainformation.com/Generation-Sequencing-Systems-10290041/).

Kalorama notes the following recent events:

DNAe was awarded a $51.9 Million Contract to develop semiconductor DNA sequencing platform for rapid diagnosis of antimicrobial resistant infections and influenza, from the Biomedical Advanced Research and Development Authority (BARDA). BARDA is a division of the Assistant Secretary for Preparedness and Response (ASPR) in the U.S. Department of Health and Human Services (HHS). Also, DNAe will present new data on G-BSI Blood-to-Result Test for Rapid Identification of Bloodstream Infections at The Association for Molecular Pathology (AMP) 2016.
Illumina's Grail to Raise $1 Billion in Series B. Grail was spun out of the genetic sequencing giant Illumina to develop its blood-based cancer testing service and leverages Illumina's gene sequencing technology.
Oxford Nanopore announced £100M / $126M fundraising.
Foundation BRCA CDx becomes the first NGS companion test to get FDA approval as it receives FDA approval of FoundationFocus™ CDxBRCA as a Companion Diagnostic for Rubraca for the treatment of women with ovarian cancer.
Roche Diagnostics announced it has decided to focus solely on the Genia Technologies platform, and terminated the company's collaboration with Pacific Biosciences.

Research that eventually led to the emergence of next-generation sequencing ten years ago actually started as early as the 1970s, and Solexa (the sequencing company later acquired by Illumina) was founded in 1998. The road to where the sequencing market is today has been long and hard. Improvements in sequencing technology are still needed in order to make sequencing based diagnostic tests widely available and used by all physicians. However, the sequencing field has entered an exciting time where it is now becoming possible to realize some of the potential benefits long dreamed about by researchers and companies in this field.

DNA sequencing has successfully penetrated the research market. Today, this market is large, and is expected to continue to grow, despite funding issues and other challenges. In addition, technology advances in knowledge of the genome, and in DNA sequencing technology/platforms, will continue to fuel the growth of diagnostic applications of next generation sequencing in clinical laboratories and companies with CLIA-certified laboratories, and also in IVD companies that sell kits to clinical labs.

Kalorama Information's Next Generation Sequencing Markets report contains more developments as well as estimates and forecasts of the market. The publisher has also published reports on the market for cFDNA and sample prep for sequencing.

Please link any media or news references to our reports or data to http://www.kaloramainformation.com/.

About Kalorama Information
Kalorama Information, a division of MarketResearch.com, supplies the latest in independent medical market research in diagnostics, biotech, pharmaceuticals, medical devices and healthcare; as well as a full range of custom research services. Reports can be purchased through Kalorama's website and are also available on www.marketresearch.com and www.profound.com.

We routinely assist the media with healthcare topics. Follow us on Twitter, LinkedIn and our blog on our company website.

Press Contact:
Bruce Carlson
212 807 2262
[email protected]

SOURCE Kalorama Information